Actively Recruiting
Analysis of the CeraVe Emollient Effect on Restoring the Hydration of the Skin Barrier as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis
Led by Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse · Updated on 2025-10-02
98
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the effect of CeraVe emollient cream on restoring skin hydration in people with mild to moderate atopic dermatitis (AD). This skin condition involves inflammation and problems with the skin barrier, including reduced ceramide production. The study aims to compare CeraVe's ability to restore skin hydration with a commonly used pharmacy-made emollient and to assess differences in disease control scores between the two groups. Participants who have mild to moderate AD with significant improvement after steroid treatment will be randomly assigned to use either CeraVe or a standard emollient cream twice daily for 42 days. Both groups will use a basic detergent for washing. If a relapse occurs, participants should stop using the assigned emollient and seek medical evaluation, which will lead to withdrawal from the study. During the study, participants will be monitored over six weeks with scheduled visits to assess changes in eczema severity using the Eczema Area and Severity Index (EASI) score, cosmetic acceptability of the emollients, disease control tool scores, and skin appearance through photographs. Researchers will track relapse rates and other outcomes to evaluate the treatments' effects on skin hydration and disease maintenance.
CONDITIONS
Brief Title
CeraVe Effect on Restoring Skin Hydration as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinically confirmed mild-to-moderate atopic dermatitis with an Eczema Area and Severity Index (EASI) score between 1 and 21
- Lesions cleared after steroid treatment with at least 90% reduction in EASI score
- Participants of any gender aged 18 years or older
- Willing and able to give informed consent to participate in the study
You will not qualify if you...
- Age under 18 years
- Unwilling or unable to give informed consent
- Receiving any systemic treatment for atopic dermatitis, including corticosteroids, cyclosporine, approved biologics, or JAK inhibitors
- Having any other dermatological disorder that may interfere with accurate evaluation of skin characteristics (except atopic dermatitis)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 42 days
Participants who meet eligibility receive either CeraVe emollient or a standard emollient twice daily for maintenance following corticosteroid treatment.
3 visits (including enrollment and two follow-ups)
Trial Site Locations
Total: 1 location
1
Fondazione PTV - Policlinico Tor Vergata
Roma, RM, Italy
Actively Recruiting
Research Team
P
Prof.ssa Elena Campione
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here